Michael Klüver

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

B. Bošnjak, G. Sutter, B. Haagmans, 2021, Proceedings of the National Academy of Sciences.

No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults

S. Detmer, L. Gieselmann, S. Becker, 2022, iScience.

Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection In Vitro

M. Eickmann, S. Becker, R. Klar, 2019, Molecular therapy. Nucleic acids.

No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults

S. Detmer, L. Gieselmann, S. Becker, 2021, bioRxiv.

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

S. Ciesek, M. S. Marlow, M. Eickmann, 2021, bioRxiv.

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

B. Bošnjak, G. Sutter, B. Haagmans, 2021, bioRxiv.

The C-terminus of Sudan ebolavirus VP40 contains a functionally important CXnC motif, a target for redox modifications.

G. Klebe, A. Heine, E. Saphire, 2023, Structure.

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

M. Addo, G. Sutter, B. Haagmans, 2022, Nature Communications.